BR0211612A - Cristais que incluem um sal de ácido málico de n-[2-(dietilamino)etil]-5-[(5-flúor2-oxo-3h-indol-3-ilide no)metil]-2,4-dimetil-1h-pirrol-3-carboxamida, processos para a sua preparação e suas composições - Google Patents

Cristais que incluem um sal de ácido málico de n-[2-(dietilamino)etil]-5-[(5-flúor2-oxo-3h-indol-3-ilide no)metil]-2,4-dimetil-1h-pirrol-3-carboxamida, processos para a sua preparação e suas composições

Info

Publication number
BR0211612A
BR0211612A BR0211612-0A BR0211612A BR0211612A BR 0211612 A BR0211612 A BR 0211612A BR 0211612 A BR0211612 A BR 0211612A BR 0211612 A BR0211612 A BR 0211612A
Authority
BR
Brazil
Prior art keywords
indol
carboxamide
oxo
dimethyl
compositions
Prior art date
Application number
BR0211612-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Hawley
Thomas J Fleck
Stephen P Prescott
Mark T Maloney
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0211612(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR0211612A publication Critical patent/BR0211612A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
BR0211612-0A 2001-08-15 2002-08-13 Cristais que incluem um sal de ácido málico de n-[2-(dietilamino)etil]-5-[(5-flúor2-oxo-3h-indol-3-ilide no)metil]-2,4-dimetil-1h-pirrol-3-carboxamida, processos para a sua preparação e suas composições BR0211612A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31235301P 2001-08-15 2001-08-15
PCT/US2002/025649 WO2003016305A1 (en) 2001-08-15 2002-08-13 Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Publications (1)

Publication Number Publication Date
BR0211612A true BR0211612A (pt) 2004-08-24

Family

ID=23211067

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211612-0A BR0211612A (pt) 2001-08-15 2002-08-13 Cristais que incluem um sal de ácido málico de n-[2-(dietilamino)etil]-5-[(5-flúor2-oxo-3h-indol-3-ilide no)metil]-2,4-dimetil-1h-pirrol-3-carboxamida, processos para a sua preparação e suas composições

Country Status (42)

Country Link
US (2) US20030069298A1 (cg-RX-API-DMAC10.html)
EP (3) EP3168218B1 (cg-RX-API-DMAC10.html)
JP (1) JP4159988B2 (cg-RX-API-DMAC10.html)
KR (1) KR100639281B1 (cg-RX-API-DMAC10.html)
CN (2) CN100364991C (cg-RX-API-DMAC10.html)
AP (1) AP1660A (cg-RX-API-DMAC10.html)
AR (1) AR036261A1 (cg-RX-API-DMAC10.html)
AU (1) AU2002324684B2 (cg-RX-API-DMAC10.html)
BG (1) BG108553A (cg-RX-API-DMAC10.html)
BR (1) BR0211612A (cg-RX-API-DMAC10.html)
CA (1) CA2455050C (cg-RX-API-DMAC10.html)
CO (1) CO5550431A2 (cg-RX-API-DMAC10.html)
CU (1) CU23713B7 (cg-RX-API-DMAC10.html)
CY (1) CY1121552T1 (cg-RX-API-DMAC10.html)
CZ (1) CZ2004196A3 (cg-RX-API-DMAC10.html)
DK (2) DK1419151T3 (cg-RX-API-DMAC10.html)
EA (1) EA006445B9 (cg-RX-API-DMAC10.html)
EC (1) ECSP044975A (cg-RX-API-DMAC10.html)
ES (3) ES2453164T3 (cg-RX-API-DMAC10.html)
GE (1) GEP20063777B (cg-RX-API-DMAC10.html)
HR (1) HRP20040112B1 (cg-RX-API-DMAC10.html)
HU (1) HU229206B1 (cg-RX-API-DMAC10.html)
IL (1) IL160097A0 (cg-RX-API-DMAC10.html)
IS (1) IS7147A (cg-RX-API-DMAC10.html)
MA (1) MA27058A1 (cg-RX-API-DMAC10.html)
ME (1) ME00414B (cg-RX-API-DMAC10.html)
MX (1) MXPA04001452A (cg-RX-API-DMAC10.html)
MY (1) MY139383A (cg-RX-API-DMAC10.html)
NO (1) NO326508B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ531232A (cg-RX-API-DMAC10.html)
OA (1) OA12650A (cg-RX-API-DMAC10.html)
PL (1) PL216524B1 (cg-RX-API-DMAC10.html)
PT (2) PT1419151E (cg-RX-API-DMAC10.html)
RS (1) RS53251B (cg-RX-API-DMAC10.html)
SI (2) SI1419151T1 (cg-RX-API-DMAC10.html)
SK (1) SK902004A3 (cg-RX-API-DMAC10.html)
TN (1) TNSN04028A1 (cg-RX-API-DMAC10.html)
TR (1) TR201900509T4 (cg-RX-API-DMAC10.html)
TW (1) TWI269796B (cg-RX-API-DMAC10.html)
UA (1) UA76483C2 (cg-RX-API-DMAC10.html)
WO (1) WO2003016305A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200400706B (cg-RX-API-DMAC10.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1419151T1 (sl) 2001-08-15 2014-04-30 Pharmacia & Upjohn Company Llc Kristali, ki vključujejo sol jabolčne kisline N-(2-(dietilamino)etil)-5-((5-fluoro-1,2-dihidro-2-okso-3H-indol-3- iliden)metil)-2,4-dimetil-1H-pirol-3-karboksamida, postopki za njihovo pripravo in sestavki le-teh
PY0323128A (es) * 2002-09-10 2012-12-03 Pharmacia Italia Spa Formulacion sólida que comprende un compuesto de indolina, útil en el tratamiento de trastornos relacionados con proteina de quinasas
MXPA06003661A (es) * 2003-10-02 2006-06-05 Pharmacia & Upjohn Co Llc Sales y polimorfos de un compuesto de indolinona sustituido con pirrol.
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
PL1773811T3 (pl) * 2004-07-22 2011-02-28 Lilly Co Eli Krystaliczny zmienny hydrat soli hemibursztynianowej (s)-6-(4-(2-((3(9h-karbazol-4-iloksy)-2-hydroksypropylo)amino)-2-metylopropylo)fenoksy)-3-pirydynokarboksy amidu
AU2006245421A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
RU2399619C2 (ru) * 2005-09-19 2010-09-20 Пфайзер Продактс Инк. Твердые солевые формы замещенного пирролом 2-индолинона
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
WO2009067686A2 (en) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
CN101939314B (zh) * 2007-12-12 2014-04-02 麦迪凯姆股份公司 3-吡咯取代的2-吲哚酮的多晶型物
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2252607A2 (en) * 2008-02-21 2010-11-24 Generics [UK] Limited Novel polymorphs and processes for their preparation
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
CA2720164A1 (en) * 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
WO2009128083A1 (en) * 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
CN102066362B (zh) 2008-05-23 2014-07-30 上海医药工业研究院 二氢吲哚酮衍生物
SI2313371T1 (sl) * 2008-06-13 2013-02-28 Medichem, S.A. Postopek za pripravo soli 3-pirol substituirane 2-indolinonske jabolčne kisline
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
JP2011527330A (ja) * 2008-07-10 2011-10-27 ジェネリクス・（ユーケー）・リミテッド スニチニブリンゴ酸塩の結晶形の調製方法
CA2731605A1 (en) * 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
EP2342195B1 (en) * 2008-07-24 2014-09-10 Medichem, S.A. Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
CA2734965A1 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel crystalline form and processes for its preparation
CN102197034A (zh) * 2008-08-25 2011-09-21 基因里克斯(英国)有限公司 舒尼替尼的新型多晶型物及其制备方法
CN102177155A (zh) * 2008-10-10 2011-09-07 麦迪凯姆股份公司 一种3-吡咯取代的2-吲哚酮苹果酸盐的制备工艺
EP2181991A1 (en) * 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2896618A1 (en) 2009-01-02 2015-07-22 Hetero Research Foundation Polymorphs of sunitinib malate
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
WO2011033472A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Salts of sunitinib
EP2499133A2 (en) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
US8916716B2 (en) 2009-11-19 2014-12-23 Ranbaxy Laboratories Limited Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
WO2011092664A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
WO2011107919A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
CA2793359A1 (en) 2010-03-18 2011-09-22 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US20140178368A1 (en) 2011-04-19 2014-06-26 Leslie Lynne SHARP Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
CN104114550A (zh) 2012-03-23 2014-10-22 劳拉斯实验室私人有限公司 制备舒尼替尼及其酸加成盐的改进的方法
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
US9604968B2 (en) 2013-10-18 2017-03-28 Sun Pharmaceutical Industries Limited Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
US9278955B2 (en) 2013-10-18 2016-03-08 Sun Pharmaceutical Industries Limited Ascorbic acid salt of sunitinib
EP3524262A1 (en) 2013-11-01 2019-08-14 Pfizer Inc Vectors for expression of prostate-associated antigens
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) * 2013-12-25 2019-05-28 江苏豪森药业集团有限公司 苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) * 2014-12-05 2016-06-29 广州白云山医药集团股份有限公司白云山制药总厂 一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
US20220192989A1 (en) * 2019-04-18 2022-06-23 Meter Health, Inc. Methods and compositions for treating respiratory arrhythmias
EP3958845A1 (en) 2019-04-25 2022-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
JP7633786B2 (ja) * 2020-09-18 2025-02-20 日本化薬株式会社 スニチニブリンゴ酸塩を有効成分とする医薬錠剤
KR20240025990A (ko) 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225055B1 (en) 1990-10-15 2006-05-29 Pfizer Indole derivatives, their intermediates, process for production them and pharmaceutical compositions containing the compounds
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
CA2097208C (en) 1992-06-05 2005-02-08 Raymond Baker The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
ATE202109T1 (de) * 1993-03-12 2001-06-15 Upjohn Co Kristallines ceftiofur (freie säure)
US5665878A (en) * 1994-08-31 1997-09-09 Eli Lilly And Company Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives
DE19503966C2 (de) * 1995-02-07 1998-07-02 Mack Chem Pharm Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) * 1995-05-30 1997-01-28 Motorola, Inc. Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) * 1995-07-06 1997-10-07 Moore; James R. Instructional toothbrush
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US6066647A (en) * 1996-07-29 2000-05-23 Pfizer Inc. Zwitterionic forms of trovafloxacin
SI9720059B (sl) 1996-08-14 2011-11-30 Searle & Co Kristalinična oblika 4-/5-metil-3-fenilizoksazol-4-il/benzensulfonamida
CN1104378C (zh) * 1996-12-25 2003-04-02 日本化药株式会社 顺铂细粉及其制备方法
US5777185A (en) * 1997-09-09 1998-07-07 Laroche Industries Inc. Production of organic fluorine compounds
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) * 1998-01-26 2000-01-11 The Boeing Company Galley vacuum waste disposal system
PL200710B1 (pl) 1998-06-19 2009-01-30 Teijin Pharma Ltd Polimorfy kwasu 2-(3-cyjano-4-izobutyloksyfenylo)-4-metylo-5-tiazolokarboksylowego i sposób ich wytwarzania
DE69906152T2 (de) * 1998-12-17 2004-02-12 F. Hoffmann-La Roche Ag 4-alkenyl (und alkinyl)oxoindole als inhibitoren cyclinabhängiger kinasen, insbesondere cdk2
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
JP5336686B2 (ja) * 1999-11-24 2013-11-06 スージェン， インク． 遊離酸または遊離塩基としてイオン化可能な医薬品のための処方
HRP20020751B1 (hr) * 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
US6316672B1 (en) * 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
SI1419151T1 (sl) 2001-08-15 2014-04-30 Pharmacia & Upjohn Company Llc Kristali, ki vključujejo sol jabolčne kisline N-(2-(dietilamino)etil)-5-((5-fluoro-1,2-dihidro-2-okso-3H-indol-3- iliden)metil)-2,4-dimetil-1H-pirol-3-karboksamida, postopki za njihovo pripravo in sestavki le-teh
EP2252607A2 (en) 2008-02-21 2010-11-24 Generics [UK] Limited Novel polymorphs and processes for their preparation
WO2009156837A2 (en) 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt

Also Published As

Publication number Publication date
ZA200400706B (en) 2005-05-25
BG108553A (bg) 2005-04-30
RS53251B (sr) 2014-08-29
NO326508B1 (no) 2008-12-15
OA12650A (en) 2006-06-19
EP3168218B1 (en) 2018-11-14
HU229206B1 (en) 2013-09-30
UA76483C2 (en) 2006-08-15
KR100639281B1 (ko) 2006-10-31
TR201900509T4 (tr) 2019-02-21
EP1419151B1 (en) 2014-02-26
PT3168218T (pt) 2019-01-11
MY139383A (en) 2009-09-30
US7435832B2 (en) 2008-10-14
AP1660A (en) 2006-09-09
JP4159988B2 (ja) 2008-10-01
ECSP044975A (es) 2004-03-23
HUP0700036A2 (en) 2008-10-28
PT1419151E (pt) 2014-03-27
AR036261A1 (es) 2004-08-25
IL160097A0 (en) 2004-06-20
CN100364991C (zh) 2008-01-30
CY1121552T1 (el) 2020-05-29
SI3168218T1 (sl) 2019-05-31
EA006445B1 (ru) 2005-12-29
ES2705063T3 (es) 2019-03-21
EP3168218A1 (en) 2017-05-17
PL216524B1 (pl) 2014-04-30
EP2332934B1 (en) 2017-03-01
SI1419151T1 (sl) 2014-04-30
DK1419151T3 (da) 2014-03-31
SK902004A3 (sk) 2005-03-04
HK1088008A1 (zh) 2006-10-27
CN100439360C (zh) 2008-12-03
RS10304A (sr) 2007-02-05
CU20040029A7 (es) 2008-03-14
IS7147A (is) 2004-02-10
CO5550431A2 (es) 2005-08-31
ES2623094T3 (es) 2017-07-10
GEP20063777B (en) 2006-03-27
WO2003016305A1 (en) 2003-02-27
ME00414B (me) 2011-10-10
HK1066542A1 (en) 2005-03-24
MXPA04001452A (es) 2004-05-20
AU2002324684B2 (en) 2006-10-05
EP2332934A1 (en) 2011-06-15
HRP20040112B1 (en) 2012-03-31
PL368317A1 (en) 2005-03-21
KR20040030074A (ko) 2004-04-08
CN1543462A (zh) 2004-11-03
MA27058A1 (fr) 2004-12-20
NZ531232A (en) 2004-11-26
CN1789264A (zh) 2006-06-21
CA2455050C (en) 2007-02-20
JP2005503386A (ja) 2005-02-03
EA006445B9 (ru) 2017-02-28
CZ2004196A3 (cs) 2005-01-12
ES2453164T3 (es) 2014-04-04
EP1419151A1 (en) 2004-05-19
EA200400183A1 (ru) 2004-08-26
TNSN04028A1 (fr) 2006-06-01
TWI269796B (en) 2007-01-01
CA2455050A1 (en) 2003-02-27
US20030069298A1 (en) 2003-04-10
DK3168218T3 (en) 2019-01-14
AP2004002976A0 (en) 2004-03-31
HRP20040112A2 (en) 2004-06-30
US20070191458A1 (en) 2007-08-16
NO20041054L (no) 2004-03-12
CU23713B7 (es) 2011-10-05

Similar Documents

Publication Publication Date Title
AP1660A (en) Crystals including a malic acid salt of N - [2 -(diethylamino) ethyl] - 5 - [ (5 - fluoro -2-oxo - 3H -indole -3 - ylidene) methyl] - 2,4 - dimethyl - 1H- pyrrole -3 -carboxamide, processes for its preparation and compositions thereof.
EA200602196A1 (ru) Производные пиразола, композиции, содержащие эти соединения, и способы применения
DK1353917T3 (da) Ny fremgangsmåde til syntesen af 5-(4-fluorphenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrol-3-carboxylsyre phenylamid
DK0711280T3 (da) Perhydroisoindolderivater, fremstilling af disse forbindelser og farmaceutiske præparater indeholdende disse forbindelser
DK1131318T3 (da) Fremgangsmåde til fremstilling af 5-substituerede pyrazoler under anvendelse af dithietaner
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
ATE292118T1 (de) Pyrazolderivative als p-38 map kinase inhibitoren
BR0305258A (pt) Inibidores de polimerase de ns5b de hcv
DE69922930D1 (de) N-[(substitutierte fünfgliedrige di- oder triaza-doppeltungesättigter ring)carbonyl]guanidinderivate zur behandlung von ischemie
ATE349434T1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
DK0503548T3 (da) Cykliske ureaderivater, lægemidler indeholdende disse, og fremgangsmåde til deres fremstilling.
ATE241998T1 (de) Multikatalytische protease-inhibitoren
DE60327931D1 (de) Selektive östrogenrezeptor modulatoren, die eine phenylsulfonyl-gruppe enthalten
EE200300168A (et) Tripeptidüülpeptidaasi inhibiitorid, nende valmistamine ja kasutamine ravimina ning neid sisaldav farmatseutiline kompositsioon
BRPI0407841A (pt) inibidores heterocìclicos de quinase
DE60004340D1 (de) Substituierte 1,4-dihydroindeno[1,2-c]pyrazole als inhibitoren von tyrosinkinase
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
TR200503401T1 (tr) Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları
DK0833626T3 (da) Mono- og disulfosubstituerede anthraquioner og deres anvendelse til behandlingen af knoglematrixforstyrrelser
DE69626680D1 (de) Kondensierte isoindolone als proteinkinase c inhibitoren
ES2191621T3 (es) Tienocicloalqu(en)ilamino-1,3,5-triazinas substituidas.
BR0016991A (pt) Método para sìntese de hidrozodicarbonamida
DE60134336D1 (de) Humane ltrpc7 proteine, dafür kodierende nukleinsäuren und deren verwendungen
BR0317228A (pt) Inibidores de aminocianopiridina tricìclicos de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno
EE9900188A (et) HIV proteaasi inhibiitoritena kasulikud 1-(3-aminoindasool-5-üül)-3-fenüülmetüül-tsüklilised uuread

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07D 403/06

Ipc: C07D 403/06 (2011.01), A61P 35/00 (2011.01)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]